DK1622612T3 - Pharmaceutical formulation of the sodium salt of telmitarsan - Google Patents

Pharmaceutical formulation of the sodium salt of telmitarsan

Info

Publication number: DK1622612T3
Authority: DK; Denmark
Prior art keywords: telmitarsan; sodium salt; pharmaceutical formulation; formulation; pharmaceutical
Prior art date: 2003-04-30

Application number

DK04729635T

Other languages

Danish (da)

Inventor

Anja Kohlrausch

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-30

Filing date

2004-04-27

Publication date

2008-05-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1622612(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-27 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2008-05-26 Application granted granted Critical

2008-05-26 Publication of DK1622612T3 publication Critical patent/DK1622612T3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

DK04729635T 2003-04-30 2004-04-27 Pharmaceutical formulation of the sodium salt of telmitarsan DK1622612T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10319450A DE10319450A1 (en)	2003-04-30	2003-04-30	Pharmaceutical formulation of telmisartan sodium salt
PCT/EP2004/004425 WO2004096215A1 (en)	2003-04-30	2004-04-27	Pharmaceutical formulation of the sodium salt of telmisartan

Publications (1)

Publication Number	Publication Date
DK1622612T3 true DK1622612T3 (en)	2008-05-26

Family

ID=33305059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04729635T DK1622612T3 (en)	2003-04-30	2004-04-27	Pharmaceutical formulation of the sodium salt of telmitarsan

Country Status (22)

Country	Link
EP (1)	EP1622612B9 (en)
JP (2)	JP5156231B2 (en)
KR (1)	KR20060008943A (en)
CN (1)	CN100589802C (en)
AR (2)	AR044142A1 (en)
AT (1)	ATE388703T1 (en)
AU (1)	AU2004233581B2 (en)
BR (1)	BRPI0409809A (en)
CA (1)	CA2524091C (en)
CL (1)	CL2004000899A1 (en)
DE (2)	DE10319450A1 (en)
DK (1)	DK1622612T3 (en)
ES (1)	ES2303634T4 (en)
IL (1)	IL171465A (en)
MX (1)	MXPA05011647A (en)
NZ (1)	NZ543775A (en)
PE (1)	PE20050464A1 (en)
RU (1)	RU2372918C2 (en)
TW (1)	TWI364278B (en)
UY (1)	UY28293A1 (en)
WO (1)	WO2004096215A1 (en)
ZA (1)	ZA200507223B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10319450A1 (en) *	2003-04-30	2004-11-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical formulation of telmisartan sodium salt
DE10319592A1 (en) *	2003-05-02	2004-11-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Treatment of diabetic retinopathy with angiotensin II receptor blockers
US7943781B2 (en)	2004-10-18	2011-05-17	Dr. Reddy's Laboratories Limited	Process for preparing telmisartan
US8637078B2 (en)	2005-11-24	2014-01-28	Boehringer Ingelheim International Gmbh	Bilayer tablet comprising telmisartan and diuretic
SI2269583T1 (en)	2006-06-16	2014-12-31	Lek Pharmaceuticals D.D.	Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
TWI482772B (en)	2006-08-21	2015-05-01	Astrazeneca Ab	Compositions, suitable for oral administration, comprising a triazolo(4,5-d)pyrimidin derivate
WO2009058950A2 (en) *	2007-10-30	2009-05-07	Dr. Reddy's Laboratories Ltd.	Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
DE102008047910A1 (en)	2008-09-19	2010-03-25	Molkerei Meggle Wasserburg Gmbh & Co. Kg	Tabletting excipient based on lactose and cellulose
CZ301299B6 (en)	2008-11-24	2010-01-06	Zentiva, A.S.	Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients
SI2443094T1 (en)	2009-06-19	2013-08-30	Krka, Tovarna Zdravil, D.D., Novo Mesto	Process for the preparation of telmisartan
EP2448575A2 (en) *	2009-07-02	2012-05-09	Bilgic Mahmut	Pharmaceutical composition increasing solubility and stability
JP2011136908A (en) *	2009-12-25	2011-07-14	Kyowa Yakuhin Kogyo Kk	Solid preparation including angiotensin ii receptor antagonist and method of improving storage stability of angiotensin ii receptor antagonist in the solid preparation
CA2706292A1 (en) *	2010-05-28	2011-11-28	Pharmascience Inc.	A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2011161123A2 (en)	2010-06-21	2011-12-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
PT2640371T (en) *	2010-11-15	2020-04-17	Boehringer Ingelheim Int	Vasoprotective and cardioprotective antidiabetic therapy
US9446032B2 (en) *	2011-08-26	2016-09-20	Wockhardt Limited	Methods for treating cardiovascular disorders
CN102526037B (en) *	2012-02-10	2014-08-27	重庆康刻尔制药有限公司	Telmisartan medicinal composition, telmisartan medicinal composition tablets and preparation method for telmisartan medicinal composition tablets
EP2649996A1 (en) *	2012-04-11	2013-10-16	Laboratorios Del. Dr. Esteve, S.A.	Crystalline forms of sartans like telmisartan with beta blockers
JP6018420B2 (en) *	2012-06-05	2016-11-02	ニプロ株式会社	Pharmaceutical composition comprising an angiotensin II receptor antagonist and thiazide diuretic
JP6428340B2 (en) *	2014-05-23	2018-11-28	ニプロ株式会社	Method for granulating a pharmaceutical composition comprising telmisartan
JP5956034B1 (en) *	2015-07-27	2016-07-20	エルメッドエーザイ株式会社	Telmisartan-containing pharmaceutical composition
CN107501192A (en) *	2017-08-15	2017-12-22	中国科学院上海药物研究所	The eutectic of Telmisartan and Hydrochioro
KR20200043618A (en) *	2018-10-18	2020-04-28	주식회사유한양행	Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI9210098B (en) *	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoles, drugs with this compounds, and process for their preparation
JP4107831B2 (en) *	2000-11-21	2008-06-25	第一三共株式会社	Pharmaceutical composition
US20040242891A1 (en) *	2001-10-26	2004-12-02	Jonathan Campbell	Production of keto acids
DE10153737A1 (en) *	2001-10-31	2003-05-28	Boehringer Ingelheim Pharma	Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
EA007614B1 (en) *	2002-01-16	2006-12-29	Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг	Bilayer pharmaceutical tablet and method for producing thereof
DE10244681A1 (en) *	2002-09-24	2004-04-08	Boehringer Ingelheim International Gmbh	New solid telmisartan-containing pharmaceutical formulations and their preparation
DE10301371A1 (en) *	2003-01-16	2004-08-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases, e.g. hypertension combined with hyperlipidemia or atherosclerosis, using combination of telmisartan and atorvastatin
DE10319450A1 (en) *	2003-04-30	2004-11-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical formulation of telmisartan sodium salt

2003
- 2003-04-30 DE DE10319450A patent/DE10319450A1/en not_active Withdrawn
2004
- 2004-04-27 AU AU2004233581A patent/AU2004233581B2/en not_active Ceased
- 2004-04-27 KR KR1020057020575A patent/KR20060008943A/en active Search and Examination
- 2004-04-27 JP JP2006500100A patent/JP5156231B2/en not_active Expired - Fee Related
- 2004-04-27 ES ES04729635T patent/ES2303634T4/en not_active Expired - Lifetime
- 2004-04-27 AT AT04729635T patent/ATE388703T1/en active
- 2004-04-27 RU RU2005137031/15A patent/RU2372918C2/en not_active IP Right Cessation
- 2004-04-27 EP EP04729635A patent/EP1622612B9/en not_active Expired - Lifetime
- 2004-04-27 DK DK04729635T patent/DK1622612T3/en active
- 2004-04-27 CN CN200480011725A patent/CN100589802C/en not_active Expired - Fee Related
- 2004-04-27 NZ NZ543775A patent/NZ543775A/en not_active IP Right Cessation
- 2004-04-27 WO PCT/EP2004/004425 patent/WO2004096215A1/en active IP Right Grant
- 2004-04-27 DE DE502004006500T patent/DE502004006500D1/en not_active Expired - Lifetime
- 2004-04-27 BR BRPI0409809-9A patent/BRPI0409809A/en not_active Application Discontinuation
- 2004-04-27 CA CA2524091A patent/CA2524091C/en not_active Expired - Fee Related
- 2004-04-27 MX MXPA05011647A patent/MXPA05011647A/en active IP Right Grant
- 2004-04-28 PE PE2004000417A patent/PE20050464A1/en not_active Application Discontinuation
- 2004-04-28 UY UY28293A patent/UY28293A1/en not_active Application Discontinuation
- 2004-04-28 CL CL200400899A patent/CL2004000899A1/en unknown
- 2004-04-29 TW TW093112090A patent/TWI364278B/en not_active IP Right Cessation
- 2004-04-30 AR ARP040101480A patent/AR044142A1/en active Pending
2005
- 2005-09-08 ZA ZA200507223A patent/ZA200507223B/en unknown
- 2005-10-19 IL IL171465A patent/IL171465A/en not_active IP Right Cessation
2010
- 2010-03-16 JP JP2010059404A patent/JP5254268B2/en not_active Expired - Fee Related
2012
- 2012-07-17 AR ARP120102583A patent/AR087210A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA05011647A (en)	2005-12-15
DE10319450A1 (en)	2004-11-18
JP2010138207A (en)	2010-06-24
JP5156231B2 (en)	2013-03-06
EP1622612B9 (en)	2008-11-05
ES2303634T3 (en)	2008-08-16
ATE388703T1 (en)	2008-03-15
ES2303634T4 (en)	2009-04-01
CL2004000899A1 (en)	2005-03-04
WO2004096215A1 (en)	2004-11-11
CN1780618A (en)	2006-05-31
TWI364278B (en)	2012-05-21
UY28293A1 (en)	2004-11-30
TW200509914A (en)	2005-03-16
JP2006524635A (en)	2006-11-02
ZA200507223B (en)	2006-05-31
RU2005137031A (en)	2007-06-10
AR044142A1 (en)	2005-08-24
CN100589802C (en)	2010-02-17
AU2004233581B2 (en)	2010-04-22
KR20060008943A (en)	2006-01-27
RU2372918C2 (en)	2009-11-20
BRPI0409809A (en)	2006-05-09
EP1622612B1 (en)	2008-03-12
AR087210A2 (en)	2014-02-26
DE502004006500D1 (en)	2008-04-24
NZ543775A (en)	2009-03-31
CA2524091A1 (en)	2004-11-11
IL171465A (en)	2010-06-30
EP1622612A1 (en)	2006-02-08
AU2004233581A1 (en)	2004-11-11
CA2524091C (en)	2012-02-21
JP5254268B2 (en)	2013-08-07
PE20050464A1 (en)	2005-07-04

Publication	Publication Date	Title
DK1622612T3 (en)	2008-05-26	Pharmaceutical formulation of the sodium salt of telmitarsan
CY2017048I1 (en)	2018-09-05	NEW PHARMACEUTICAL USES OF STAVROSPORINE DERIVATIVES
DK2172205T3 (en)	2014-07-14	Pharmaceutical formulation consisting of lanthanum compounds
PT1501534E (en)	2006-09-29	PHARMACEUTICAL FORMULATIONS
DE602004017700D1 (en)	2008-12-24	TRANSMUKOSEN ADMINISTRATION
DK3395338T3 (en)	2019-07-22	QUICK SOLVING FORMULATION OF CINACALCET-HCL
DK3536344T3 (en)	2020-03-16	SUPERFIN FORMOTHER FORMULATION
CY2018005I2 (en)	2018-06-27	ORAL PHARMACEUTICAL FORMS OF CLANTRIVINE
PT1467724E (en)	2006-08-31	AGOMELATIN ORODISPERSAVEL PHARMACEUTICAL COMPOSITION
DK1601359T3 (en)	2009-01-05	Liquid pharmaceutical formulations of palonosetron
DK1587478T3 (en)	2013-10-21	PHARMACEUTICAL COMPOSITION
DK1651044T3 (en)	2008-05-13	Liquid preparation
ATE309789T1 (en)	2005-12-15	PHARMACEUTICAL FORM OF IBUPROFEN SODIUM
DE602004014547D1 (en)	2008-08-07	fundus camera
DK1516540T3 (en)	2012-11-26	Use of vitamin D compounds
DK1643976T3 (en)	2009-04-06	Pharmaceutical formulation comprising levothyroxine sodium
ATE448780T1 (en)	2009-12-15	MODIFIED RELEASE PHARMACEUTICAL MODAFINIL COMPOSITIONS
ITMI20031994A1 (en)	2005-04-16	PROCEDURE FOR THE PREPARATION OF FLUDARABINA FOSFATO
NO20034952D0 (en)	2003-11-06	Pharmaceutical compounds
ITMI20030018A1 (en)	2004-07-10	PROCEDURE FOR THE PREPARATION OF SINGLE COMPOUNDS
NO20044164L (en)	2004-09-30	Pharmaceutical compositions
DE112004001429D2 (en)	2006-04-13	Pharmaceutical agent
ITMI20030019A1 (en)	2004-07-10	PROCEDURE FOR THE PREPARATION OF SINGLE COMPOUNDS
PT1467737E (en)	2006-08-31	PHARMACEUTICAL COMPOSITION ORODISPERSIVEL OF PYRIBEDIL
SE0200449D0 (en)	2002-02-13	Pharmaceutical formulation